Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (31249)	12/11/2002 9:16:26 PM
From: Arthur Radley	Read Replies (2) \| Respond to of 32384

Bob, I'm really liking the action in LGND...as of late! As for MLNM, Ron Garren at InvestBio has been high on their efforts. The following is his report issued tonight about the ASH conference and what he has to say about MLNM... "Another new target is the proteosome and the key player here is Millennium’s Velcade. I won’t go into details of the biology but I want to mention that followup data on the Phase II myeloma trial were very impressive with durable remissions in patients with terrible disease that was refractory to multiple other therapies. Also at ASH there was a paper indicating that Velcade may have activity in some resistant lymphomas, which could open up a much bigger market than myeloma (everyone is waiting to see if Velcade works in combination chemotherapy for refractory solid tumors—this would truly make it a major drug in terms of sales). " Happy HOLIDAY!